IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2

Cardiovascular Research

Volumn 64, Issue 1, 2004, Pages 61-71

  Dawn, Buddhadeb ^b   Xuan, Yu Ting ^b   Guo, Yiru ^b   Rezazadeh, Arash ^b   Stein, Adam B ^b   Hunt, Greg ^b   Wu, Wen Jian ^b   Tan, Wei ^b   Bolli, Roberto ^a  

^a University of Louisville School of Medicine   (United States)

^b NONE

Author keywords

Cyclooxygenase; Infarction; Interleukins; Preconditioning; Signal transduction

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; STAT 1 PROTEIN; STAT 3 PROTEIN; STAT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE REPERFUSION; HEART PROTECTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STIMULATION; TIME; UPREGULATION; WILD TYPE;

ANIMALS; CELL NUCLEUS; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; ISCHEMIC PRECONDITIONING, MYOCARDIAL; ISOENZYMES; JANUS KINASE 1; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 4444377395     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.05.011     Document Type: Article

References (32)

1. Kuzuya T., Hoshida S., Yamashita N., et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ. Res. 72:1993;1293-1299
2. Bolli R. The late phase of preconditioning. Circ. Res. 87:2000;972-983
3. Yellon D.M., Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev. 83:2003;1113-1151
4. Xuan Y.T., Guo Y., Han H., Zhu Y., Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9050-9055
5. Xuan Y.T., Guo Y., Zhu Y., et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J. Mol. Cell. Cardiol. 35:2003;525-537
6. Hirano T. The biology of interleukin-6. Chem. Immunol. 51:1992;153-180
7. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334:1998;297-314
8. Hirano T. Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. 16:1998;249-284
9. Hirano T., Nakajima K., Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 8:1997;241-252
10. Kukielka G.L., Smith C.W., Manning A.M., Youker K.A., Michael L.H., Entman M.L. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation. 92:1995;1866-1875
11. Chandrasekar B., Mitchell D.H., Colston J.T., Freeman G.L. Regulation of CCAAT/enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion. Circulation. 99:1999;427-433
12. Gwechenberger M., Mendoza L.H., Youker K.A., et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 99:1999;546-551
13. Yamauchi-Takihara K., Ihara Y., Ogata A., Yoshizaki K., Azuma J., Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 91:1995;1520-1524
14. Guo Y., Wu W.J., Qiu Y., Tang X.L., Yang Z., Bolli R. Demonstration of an early and a late phase of ischemic preconditioning in mice. Am. J. Physiol. 275:1998;H1375-H1387
15. Guo Y., Jones W.K., Xuan Y.T., et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc. Natl. Acad. Sci. U.S.A. 96:1999;11112-11507
16. Shinmura K., Tang X.L., Wang Y., et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10197-10202
17. Xuan Y.T., Tang X.L., Qiu Y., et al. Biphasic response of cardiac NO synthase isoforms to ischemic preconditioning in conscious rabbits. Am. J. Physiol., Heart Circ. Physiol. 279:2000;H2360-H2371
18. Fuchs M., Hilfiker A., Kaminski K., et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J. 17:2003;2118-2120
19. Imada K., Leonard W.J. The JAK-STAT pathway. Mol. Immunol. 37:2000;1-11
20. Willis R.A., Nussler A.K., Fries K.M., Geller D.A., Phipps R.P. Induction of nitric oxide synthase in subsets of murine pulmonary fibroblasts: effect on fibroblast interleukin-6 production. Clin. Immunol. Immunopathol. 71:1994;231-239
21. Ianaro A., O'Donnell C.A., Di Rosa M., Liew F.Y. A nitric oxide synthase inhibitor reduces inflammation, down-regulates inflammatory cytokines and enhances interleukin-10 production in carrageenin-induced oedema in mice. Immunology. 82:1994;370-375
22. Bolli R., Manchikalapudi S., Tang X.L., et al. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase: evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ. Res. 81:1997;1094-1107
23. Takano H., Manchikalapudi S., Tang X.L., et al. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation. 98:1998;441-449
24. Guo Y., Xuan Y.T., Wu W.J., Li Q., Tang X.L., Bolli R. Nitric oxide plays a dual role in exercise-induced late preconditioning. Circulation. 104(Suppl. II):2001;II-60
25. Zhao T.C., Kukreja R.C. Late preconditioning elicited by activation of adenosine A(3) receptor in heart: role of NF-kappa B, iNOS and mitochondrial K(ATP) channel. J. Mol. Cell. Cardiol. 34:2002;263-277
26. Xuan Y.T., Tang X.L., Banerjee S., et al. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ. Res. 84:1999;1095-1109
27. Xie Q.W., Whisnant R., Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med. 177:1993;1779-1784
28. Sakitani K., Nishizawa M., Inoue K., Masu Y., Okumura T., Ito S. Synergistic regulation of inducible nitric oxide synthase gene by CCAAT/enhancer-binding protein beta and nuclear factor-kappaB in hepatocytes. Genes Cells. 3:1998;321-330
29. Saura M., Zaragoza C., Bao C., McMillan A., Lowenstein C.J. Interaction of interferon regulatory factor-1 and nuclear factor kappaB during activation of inducible nitric oxide synthase transcription. J. Mol. Biol. 289:1999;459-471
30. Gao J., Morrison D.C., Parmely T.J., Russell S.W., Murphy W.J. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J. Biol. Chem. 272:1997;1226-1230
31. Yu X., Kennedy R.H., Liu S.J. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J. Biol. Chem. 278:2003;16304-16309
32. Kinugawa K., Shimizu T., Yao A., Kohmoto O., Serizawa T., Takahashi T. Transcriptional regulation of inducible nitric oxide synthase in cultured neonatal rat cardiac myocytes. Circ. Res. 81:1997;911-921